2019
Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production
Cotzomi E, Stathopoulos P, Lee CS, Ritchie AM, Soltys JN, Delmotte FR, Oe T, Sng J, Jiang R, K A, Vander Heiden JA, Kleinstein SH, Levy M, Bennett JL, Meffre E, O’Connor K. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain 2019, 142: 1598-1615. PMID: 31056665, PMCID: PMC6536857, DOI: 10.1093/brain/awz106.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderB cell tolerance checkpointsNMOSD patientsNaïve B cellsAQP4 autoantibodiesTolerance checkpointsHealthy donorsB cellsEarly B cell tolerance checkpointsPeripheral B cell tolerance checkpointsMature naïve B cellsB cell tolerance defectsSeropositive NMOSD patientsOptica spectrum disorderRare autoimmune disorderNaïve B-cell compartmentB cell compartmentB cell populationsAquaporin-4 water channelsPathogenic autoantibodiesAutoantibody productionOptic nerveAutoimmune disordersSevere inflammationSpinal cordAutoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity
Stathopoulos P, Chastre A, Waters P, Irani S, Fichtner ML, Benotti ES, Guthridge JM, Seifert J, Nowak RJ, Buckner JH, Holers VM, James JA, Hafler DA, O’Connor K. Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. The Journal Of Immunology 2019, 202: ji1801295. PMID: 30824481, PMCID: PMC6452031, DOI: 10.4049/jimmunol.1801295.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusRheumatoid arthritisControl cohortNeuromyelitis optica spectrum disorderSurface AgOptica spectrum disorderMyelin oligodendrocyte glycoproteinHealthy donor seraType 1 diabetesB cell toleranceNeurologic autoimmunitySLE patientsLupus erythematosusSuch autoantibodiesT1D patientsAutoimmune diseasesHigh titer AbsOligodendrocyte glycoproteinSystemic autoimmunityDonor seraLarge cohortRare caseAutoantibodiesAquaporin-4Cell tolerance
2016
Restoring immune tolerance in neuromyelitis optica
Bar-Or A, Steinman L, Behne J, Benitez-Ribas D, Chin P, Clare-Salzler M, Healey D, Kim J, Kranz D, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei C, Weiner H, Zamvil S, Smith T, Yeaman M, Aktas O, Amezcua L, Appiwatanakul M, Asgari N, Banwell B, Bennett J, Bowen J, Cabre P, Chitnis T, Cohen J, De Seze J, Fujihara K, Han M, Hellwig K, Hintzen R, Hooper D, Iorio R, Jacob A, Jarius S, Kim H, Kissani N, Klawiter E, Kleiter I, Lana-Peixoto M, Leite M, Levy M, Lublin F, Draayer Y, Marignier R, Matiello M, Nakashima I, O’Connor K, Palace J, Pandit L, Paul F, Prayoonwiwat N, Riley C, Ruprecht K, Saiz A, Siritho S, Tenembaum S, Weinshenker B, Wingerchuk D, Würfel J. Restoring immune tolerance in neuromyelitis optica. Neurology Neuroimmunology & Neuroinflammation 2016, 3: &na;. PMID: 27648464, PMCID: PMC5015540, DOI: 10.1212/nxi.0000000000000277.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNMO/SDImmune toleranceAquaporin-4Neuromyelitis optica spectrum disorderNormal host defense mechanismsOptica spectrum disorderHost defense mechanismsOral tolerizationNeuromyelitis opticaOptic nerveParticular brain regionsAutoimmune diseasesAstrocyte functionSpinal cordClinical variantsNovel therapiesDominant autoantigenClinical developmentPotential cureB cellsBrain regionsExperimental modelDiseaseCharacteristic phenotypeAutoantigens